The ticagrelor
Phase 3Small molecule
The ticagrelor is one of 21 small molecule programs targeting Platelet Aggregation. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Platelet Aggregation
#DrugCompanyPhaseTrials
1Brilinta
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Plavix
SanofiApproved
Pradaxa
Boehringer IngelheimApproved
Versed
CConrado Roberto Hoffmann Filho
Approved
Pletal
OtsukaApproved
Duragesic
CCephalon
Approved
Zetia
OOrganon and Co
Approved
Cyklokapron
JJ Molner
Approved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for The ticagrelor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details